Oral tolerance is a well-characterized phenomenon in animals and is highly
effective when induced as a treatment for experimental autoimmune disease.
However, its use as a therapeutic modality for the treatment of autoimmune
disease in humans has been disappointing. Much of the rationale for its use
in humans is based on the finding that feeding antigen to rodents elicits
regulatory T cells in Peyer's patches (PPs) that secrete immunosuppressive
cytokines such as transforming growth factor (TGF)-beta. By contrast, human
antigen-specific PP T-cell responses, and mucosal T-cell responses in gene
ral, are strongly biased towards T helper 1 (Th1) cells, which are pro-infl
ammatory rather than immunosuppressive. This is caused by the high local Le
vels of interleukin (IL)-12 in PPs.